Product News: Polyplus-Transfection Launches a Powerful Nanotechnology for DNA Transfection Composed of JetOPTIMUS Reagents

New reagent designed to cater for increased demands of academic cell research

03 Dec 2018


Polyplus-transfection® SA, a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction and therapeutics, has announced the launch of jetOPTIMUS(R), a new reagent for powerful nanoparticle DNA transfection. 

“As cell and gene therapies become more advanced and complex, this increases the need to address DNA transfection of very challenging cells. To increase efficiency in hard-to-transfect cells, scientists have to use ever-more advanced reagents,” said Patrick Erbacher, CSO, Polyplus-transfection. “We recognized the need to combine the efficiency, safety and morphology requirements of mammalian cell transfection. To date, the market has not supplied what is expected today to fulfil all needs. Polyplus-transfection believes jetOPTIMUS will equip academics in the most advanced cell and gene therapy based research with the best solution.”

The reagent has been designed to be primarily used for research purposes across academic research in mammalian cells, especially hard-to-transfect cells. The reagent will result in the most efficient mammalian cell transfection product on the market, maximizing gene expression. This ensures improved cell viability and morphology after transfection for more relevant data. The requirement of a minimal reagent volume and DNA quantity will considerably increase cost-efficiency. The cost per reaction will be decreased by up to seven times when compared to other market leading products. 

The reagent is the latest product in the Polyplus-transfection portfolio of reagents for the transfection of genes, oligonucleotides and siRNA. jetOPTIMUS has been designed to be the best-in-class DNA transfection reagent for everyday transfection experiments. It will provide solutions for those working with all types of cells and transfection applications. It solves a range of issues encountered across the market with hard to transfect cells. 

Receive more news like this straight to your inbox, become a member for free today>>